Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence

Pharmacogenetics

Volumn 7, Issue 5, 1997, Pages 375-379

  Tyndale, Rachel F ^a,b,c   Droll, Kurt P ^a   Sellers, Edward M ^a,b,c  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Codeine; Drug metabolism; Polymorphism; Substance abuse

Indexed keywords

CODEINE; CYTOCHROME P450 ISOENZYME; HYDROCODONE; OXYCODONE;

ADULT; ALLELE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; FREQUENCY ANALYSIS; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTANT; OPIATE ADDICTION; PHENOTYPE; PRIORITY JOURNAL; RISK;

ADMINISTRATION, ORAL; ADULT; ANALGESICS, OPIOID; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; MALE; OPIOID-RELATED DISORDERS; PHENOTYPE;

MARTES PENNANTI;

EID: 0030765119     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199710000-00006     Document Type: Article

References (31)

1. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990: 39, 533-537.
2. Amir T. Personality study of alcohol, heroin, and polydrug abusers in an Arabian gulf population. Psychol Reports 1994: 74, 515-520.
3. Baum C, Kennedy DL, Knapp DE, Faich GA, Anello C. Drug utilization in the US - 1986. Rockville, Maryland: Food and Drug Administration, 1987.
4. Beaver WT, Stanley L, Wallenstein SL, Houde RW. Analgesic studies of codeine and oxycodone in patients with cancer. II Comparisons of intramuscular oxycodone with intramuscular morphine and codeine. J Pharmacol Exp Ther 1978: 207, 101-108.
5. Benowitz NL, Jacob P, Perez-Stable E. CYP2D6 phenotype and the metabolism of nicotine and cotinine. Pharmacogenetics 1996: 6, 239-242.
6. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991: 10, 545-558.
7. Chen ZR, Somogyi AA, Bochner F. Polymorphic O-demethylation of codeine. Lancet 1988: 2, 914-915.
8. Chen ZR, Somogyi AA, Bochner F. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit 1990: 12, 97-104.
9. Cholerton S, Boustead C, Taber H, Arpanahi A, Idle JR. CYP2D6 genotypes in cigarette smokers and non-tobacco users. Pharmacogenetics 1996: 6, 261-263.
10. Davis H, Baum C, Graham DJ. Indices of drug misuse for prescription drugs. Int J Addict 1991: 26, 777-795.
11. Daly AR, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang J-D, Idle JR, Ingelman-Sundberg M, Ishizaki T et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996: 6, 193-201.
12. de Morais SMF, Wilkenson GR, Balaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994: 269, 15419-15422.
13. Fernandez-Salguero P, Hoffman SM, Cholerton S, Mohrenweisser H, Raunio H, Rautio A, Pelkonen O, Huang JD, Evans WE, Idle JR, Gonzalez FJ. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2D6 genes and identification of variant CYP2A6 alleles. Am J Hum Genet 1995: 57, 651-660.
14. Flammang AM, Gelboin HV, Aoyama T, Gonzalez FJ, McCoy GD. Nicotine metabolism by cDNA-expressed human cytochrome P450s. Biochem Arch 1992: 8, 1-8.
15. Health & Welfare Canada, Narcotic, controlled and restricted drug statistics - analysis report. Health and Welfare Canada, Ottawa. 1991: 21, 41-48: 53.
16. Heim MH, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele specific PCR amplification. Lancet 1990: 336, 529-532.
17. Heim MH, Meyer UA. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 1992: 14, 49-58.
18. Korkok M. Canadian government study shows big rise in Canadian use of several narcotics. Can Med Assoc J 1979: 120, 1270-1271.
19. O'Brien CP. Drug addiction and drug abuse. In: Hardman J, Limbird L, eds. Goodman and Gilman's The pharmacological basis of therapeutics. 9th edition. Toronto: MacGraw-Hill, 1996: 557-577.
20. O'Conner LE, Berry JW, Morrison A, Brown S. The drug of choice phenomenon: psychological differences among drug users who preferred different drugs. Int J Addict 1995: 30, 541-555.
21. Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 1993a: 54, 463-472.
22. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxitine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993b: 53, 401-409.
23. Reisine T, Pasternak G. Opioid analgesics and antagonists. In: Hardman J, Limbird L, eds. Goodman and Gilman's The pharmacological basis of therapeutics. 9th edition. Toronto: MacGraw-Hill, 1996: 521-555.
24. Rosner B. Hypothesis testing: Categorical Data. In: Fundamentals of biostatistics. 2nd edition. Boston: Duxbury Press, 1988: 302-367.
25. Rounsaville BJ, Weissman MM, Kleber HD. The significance of alcoholism in treated opiate addicts. J Nerv Mem Dis 1982: 170, 479-488.
26. Sindrup SH, Brosen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995: 5, 335-346.
27. Single E, McKenzie DM. Canadian profile: alcohol and drug abuse. Toronto: Addiction Research Foundation, 1994.
28. Small LF, Eddy NB, Mosettig E, Himmelsbach CK. Studies on drug addiction (suppl 138). Washington: US Government Printing Office, 1983.
29. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schitz DA, Chu TY. The demethylation of methylenedioxymethamphetamine ('ecstasy') by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 1994: 47, 1151-1156.
30. Uhl GR. Association strategies in substance abuse. In: Jansson B, Jornvall H, Rydberg V, eds. Toward a molecular basis of alcohol use and abuse. Basal: Birkhausen, 1994: 131-141.
31. Wu D, Otton SV, Inaba T, Kalow W, Sellers EM. Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 1997, in press.